CD274 and non-small cell lung carcinoma: In this phase-III randomized trial, previously untreated patients with locally advanced or metastatic NSCLC and PD-L1 TPS ≥ 1% were randomized to receive either pembrolizumab monotherapy or Platinum-based chemotherapy as first-line systemic treatment.